Ha Hwa Jeong, Lee Jeeyong, Kim Da Yeon, Kim Jung-Soon, Shin Myung-Soon, Noh Insup, Koh Jae Soo, Kim Eun Ju, Lee Seung-Sook
Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea.
Convergence Institute of Biomedical Engineering and Biomaterials, Seoul National University of Science and Technology, Seoul 01811, Republic of Korea.
Diagnostics (Basel). 2023 Feb 14;13(4):728. doi: 10.3390/diagnostics13040728.
Fine needle aspiration cytology (FNAC) is a valuable tool for evaluating lymphadenopathy. The purpose of this study was to assess the reliability and effectiveness of FNAC in the diagnosis of lymphadenopathy.
Cytological characteristics were evaluated in 432 patients who underwent lymph node FNAC and follow-up biopsy at the Korea Cancer Center Hospital from January 2015 to December 2019.
Fifteen (3.5%) of the four hundred and thirty-two patients were diagnosed as inadequate by FNAC, with five (33.3%) of these diagnosed as metastatic carcinoma on histological examination. Of the 432 patients, 155 (35.9%) were diagnosed as benign by FNAC, with seven (4.5%) of these diagnosed histologically as metastatic carcinoma. A review of the FNAC slides, however, showed no evidence of cancer cells, suggesting that the negative results may have been due to FNAC sampling errors. An additional five samples regarded as benign on FNAC were diagnosed as non-Hodgkin lymphoma (NHL) by histological examination. Of the 432 patients, 223 (51.6%) were cytologically diagnosed as malignant, with 20 (9.0%) of these diagnosed as tissue insufficient for diagnosis (TIFD) or benign on histological examination. A review of the FNAC slides of these 20 patients, however, showed that 17 (85.0%) were positive for malignant cells. The sensitivity, specificity, positive predictive value (PPV), negative predictive values (NPV), and accuracy of FNAC were 97.8%, 97.5%, 98.7%, 96.0%, and 97.7%, respectively.
Preoperative FNAC was safe, practical, and effective in the early diagnosis of lymphadenopathy. This method, however, had limitations in some diagnoses, suggesting that additional attempts may be required according to the clinical situation.
细针穿刺细胞学检查(FNAC)是评估淋巴结病的一种有价值的工具。本研究的目的是评估FNAC在淋巴结病诊断中的可靠性和有效性。
对2015年1月至2019年12月在韩国癌症中心医院接受淋巴结FNAC及后续活检的432例患者的细胞学特征进行评估。
432例患者中有15例(3.5%)FNAC诊断为不充分,其中5例(33.3%)组织学检查诊断为转移性癌。432例患者中,155例(35.9%)FNAC诊断为良性,其中7例(4.5%)组织学诊断为转移性癌。然而,对FNAC涂片的复查显示没有癌细胞的证据,这表明阴性结果可能是由于FNAC采样误差所致。另外5例FNAC认为良性的样本组织学检查诊断为非霍奇金淋巴瘤(NHL)。432例患者中,223例(51.6%)细胞学诊断为恶性,其中20例(9.0%)组织学检查诊断为组织诊断不足(TIFD)或良性。然而,对这20例患者的FNAC涂片复查显示,17例(85.0%)有恶性细胞阳性。FNAC的敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)和准确性分别为97.8%、97.5%、98.7%、96.0%和97.7%。
术前FNAC在淋巴结病的早期诊断中安全、实用且有效。然而,该方法在某些诊断中存在局限性,这表明可能需要根据临床情况进行进一步检查。